{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T19:54:36Z","timestamp":1791748476015,"version":"4.3.4"},"reference-count":49,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Belgian Foundation against cancer.","award":["Mesothelioma call - 2016"],"award-info":[{"award-number":["Mesothelioma call - 2016"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The potential of dendritic cell (DC)-based immunotherapy to treat cancer is, nowadays, well documented. Still, the clinical success of immune checkpoint inhibitors has dampened the interest in anticancer DC vaccination. For highly life-threatening tumors that are regarded as nonimmunogenic, such as mesothelioma, however, T helper 1 immunity-biased DC-based immunotherapy could still represent an attractive strategy. In this study, we took advantage of photodynamic therapy (PDT) to induce immunogenic cell death to generate mesothelioma cell lysates for DC priming and evaluated such a vaccine to treat peritoneal mesothelioma. We found that the white light in vitro activation of the photosensitizer OR141 led to mesothelioma cell death, together with the release of bona fide danger signals that promote DC maturation. The administration of a PDT-based DC vaccine to mice bearing peritoneal mesothelioma led to highly significant survival when compared with sham or control animals treated with anti-CTLA4 antibodies. This was further supported by a strong CD8+ and CD4+ T cell response, characterized by an increased proliferation, cytotoxic activities and the expression of activation markers, including interferon gamma (IFN\u03b3). Moreover, the PDT-based DC vaccine led to a significant increase in IFN\u03b3+ T cells infiltered within mesothelioma, as determined by flow cytometry and immunohistochemistry. Finally, in vivo tracking of intraperitoneally administered DCs led us to document rapid chemotaxis towards tumor-occupied lymphatics (vs. lipopolysaccharide (LPS)-treated DC). DCs pulsed with PDT-killed mesothelioma cells also exhibited a significant increase in CCR7 receptors, together with an intrinsic capacity to migrate towards the lymph nodes. Altogether, these results indicate that PDT-based DC vaccination is particularly suited to induce a potent immune response against peritoneal mesothelioma.<\/jats:p>","DOI":"10.3390\/cancers12030545","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T07:35:30Z","timestamp":1583134530000},"page":"545","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Photodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma"],"prefix":"10.3390","volume":"12","author":[{"given":"Natalia","family":"Trempolec","sequence":"first","affiliation":[{"name":"Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Exp\u00e9rimentale et Clinique (IREC), UCLouvain, 1200 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Doix","sequence":"additional","affiliation":[{"name":"Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Exp\u00e9rimentale et Clinique (IREC), UCLouvain, 1200 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charline","family":"Degavre","sequence":"additional","affiliation":[{"name":"Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Exp\u00e9rimentale et Clinique (IREC), UCLouvain, 1200 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6499-9648","authenticated-orcid":false,"given":"Davide","family":"Brusa","sequence":"additional","affiliation":[{"name":"Institut de Recherche Exp\u00e9rimentale et Clinique (IREC) Flow Cytometry Platform, UCLouvain, 1200 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bouzin","sequence":"additional","affiliation":[{"name":"Institut de Recherche Exp\u00e9rimentale et Clinique (IREC) 2IP, UCLouvain, 1200 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Riant","sequence":"additional","affiliation":[{"name":"Institute of Condensed Matter and Nanosciences (IMCN), Molecular Chemistry, Materials and Catalysis, UCLouvain, 1348 Louvain-la-Neuve, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5360-0286","authenticated-orcid":false,"given":"Olivier","family":"Feron","sequence":"additional","affiliation":[{"name":"Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Exp\u00e9rimentale et Clinique (IREC), UCLouvain, 1200 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/sj.bjc.6690105","article-title":"The European mesothelioma epidemic","volume":"79","author":"Peto","year":"1999","journal-title":"Br. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bcp.2016.07.012","article-title":"New therapeutic strategies for malignant pleural mesothelioma","volume":"123","author":"Bonelli","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): Preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_6","first-page":"1569","article-title":"Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma","volume":"13","author":"Zimmerman","year":"2018","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1164\/rccm.201608-1755CI","article-title":"Checkpoint Blockade in Lung Cancer and Mesothelioma","volume":"196","author":"Lievense","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1093\/annonc\/mdv101","article-title":"Searching for targets for the systemic therapy of mesothelioma","volume":"26","author":"Stahel","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e1638211","DOI":"10.1080\/2162402X.2019.1638211","article-title":"Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes","volume":"8","author":"Klampatsa","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"342","DOI":"10.4161\/cbt.4.3.1644","article-title":"Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma","volume":"4","author":"Delong","year":"2005","journal-title":"Cancer Boil. Ther."},{"key":"ref_13","first-page":"1755","article-title":"Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression","volume":"11","author":"Lievense","year":"2016","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e1082028","DOI":"10.1080\/2162402X.2015.1082028","article-title":"Human mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomes","volume":"5","author":"Cornwall","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrc3258","article-title":"Cancer immunotherapy via dendritic cells","volume":"12","author":"Palucka","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.201508-1573OC","article-title":"Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma","volume":"193","author":"Cornelissen","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1158\/1078-0432.CCR-17-2522","article-title":"Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human","volume":"24","author":"Aerts","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","article-title":"Clinical use of dendritic cells for cancer therapy","volume":"15","author":"Anguille","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"328ra27","DOI":"10.1126\/scitranslmed.aae0105","article-title":"Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma","volume":"8","author":"Garg","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3389\/fonc.2019.00811","article-title":"Low Photosensitizer Dose and Early Radiotherapy Enhance Antitumor Immune Response of Photodynamic Therapy-Based Dendritic Cell Vaccination","volume":"9","author":"Doix","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1038\/onc.2015.474","article-title":"A new ER-specific photosensitizer unravels (1)O2-driven protein oxidation and inhibition of deubiquitinases as a generic mechanism for cancer PDT","volume":"35","author":"Pinto","year":"2015","journal-title":"Oncogene"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3389\/fonc.2018.00393","article-title":"Preclinical Evaluation of White Led-Activated Non-porphyrinic Photosensitizer OR141 in 3D Tumor Spheroids and Mouse Skin Lesions","volume":"8","author":"Doix","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1084\/jem.191.2.201","article-title":"Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells","volume":"191","author":"Lane","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_24","first-page":"1071","article-title":"T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors","volume":"59","author":"Marzo","year":"1999","journal-title":"Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00262-008-0500-y","article-title":"Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8+ T cell recruitment and low relative regulatory T cell infiltration","volume":"57","author":"Driessens","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3322\/caac.20132","article-title":"Immunotherapy of cancer in 2012","volume":"62","author":"Kirkwood","year":"2012","journal-title":"CA Cancer J. Clin."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00262-004-0653-2","article-title":"Tumor antigen-specific T helper cells in cancer immunity and immunotherapy","volume":"54","author":"Knutson","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/cdd.2016.5","article-title":"Immunogenic versus tolerogenic phagocytosis during anticancer therapy: Mechanisms and clinical translation","volume":"23","author":"Garg","year":"2016","journal-title":"Cell Death Differ."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.celrep.2018.06.052","article-title":"OX40 Costimulation Inhibits Foxp3 Expression and Treg Induction via BATF3-Dependent and Independent Mechanisms","volume":"24","author":"Zhang","year":"2018","journal-title":"Cell Rep."},{"key":"ref_30","first-page":"12","article-title":"Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state","volume":"63","author":"Krooshoop","year":"2003","journal-title":"Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1038\/s41467-018-04804-6","article-title":"Glycolytic metabolism is essential for CCR7 oligomerization and dendritic cell migration","volume":"9","author":"Guak","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.3389\/fimmu.2019.01168","article-title":"Lymphatic Migration of Immune Cells","volume":"10","author":"Hampton","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.immuni.2010.04.017","article-title":"Immobilized chemokine fields and soluble chemokine gradients cooperatively shape migration patterns of dendritic cells","volume":"32","author":"Schumann","year":"2010","journal-title":"Immunity"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.celrep.2016.01.048","article-title":"Intralymphatic CCL21 Promotes Tissue Egress of Dendritic Cells through Afferent Lymphatic Vessels","volume":"14","author":"Russo","year":"2016","journal-title":"Cell Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1523-1747.2000.00084.x","article-title":"Formation and kinetics of MHC class I-ovalbumin peptide complexes on immature and mature murine dendritic cells","volume":"115","author":"Kukutsch","year":"2000","journal-title":"J. Investig. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.4049\/jimmunol.171.5.2251","article-title":"Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism","volume":"171","author":"Xu","year":"2003","journal-title":"J. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Verma, V., Wegner, R.E., Adeberg, S., Horne, Z.D., Grover, S., Friedberg, J.S., and Simone, C.B. (2019). Management of Clinically Lymph Node-Positive Malignant Pleural Mesothelioma. Semin. Thorac. Cardiovasc. Surg.","DOI":"10.1053\/j.semtcvs.2019.06.004"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2174\/2212697X03666160218215744","article-title":"Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors","volume":"3","author":"Zhao","year":"2016","journal-title":"Clin. Cancer Drugs"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"208ra147","DOI":"10.1126\/scitranslmed.3006941","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"5","author":"Hassan","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1164\/rccm.200909-1465OC","article-title":"Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma","volume":"181","author":"Hegmans","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1164\/rccm.200501-057OC","article-title":"Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells","volume":"171","author":"Hegmans","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"280","DOI":"10.21037\/tlcr.2019.05.05","article-title":"A multicenter, randomized, phase II\/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial","volume":"8","author":"Belderbos","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1470-2045(06)70985-8","article-title":"Combination of chemotherapy and immunotherapy for cancer: A paradigm revisited","volume":"8","author":"Gabrilovich","year":"2007","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.3747\/co.v18i3.783","article-title":"Impact of tumour volume on the potential efficacy of therapeutic vaccines","volume":"18","author":"Gulley","year":"2011","journal-title":"Curr. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/jnci\/djs033","article-title":"Therapeutic cancer vaccines: Current status and moving forward","volume":"104","author":"Schlom","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_47","first-page":"472","article-title":"Radical pleurectomy and photodynamic therapy for malignant pleural mesothelioma","volume":"1","author":"Friedberg","year":"2012","journal-title":"Ann. Cardiothorac. Surg."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/j.athoracsur.2011.02.062","article-title":"Photodynamic therapy and the evolution of a lung-sparing surgical treatment for mesothelioma","volume":"91","author":"Friedberg","year":"2011","journal-title":"Ann. Thorac. Surg."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.trecan.2017.12.007","article-title":"Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment","volume":"4","author":"Saxena","year":"2018","journal-title":"Trends Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/3\/545\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:02:04Z","timestamp":1760173324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/3\/545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":49,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["cancers12030545"],"URL":"https:\/\/doi.org\/10.3390\/cancers12030545","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,27]]}}}